Sarepta soars as DMD therapy makes major strides but challenges lay ahead
This article was originally published in Scrip
Impressive improvements in six-minute walk test (6MWT) results for Duchenne muscular dystrophy (DMD) patients at 48 weeks of treatment with the exon-skipping drug eteplirsen caused Sarepta Therapeutics' stock price to triple on the Nasdaq, as long-term Phase IIb data demonstrated the greatest efficacy for a DMD therapy to date.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.